Clay Siegall’s quest to fight cancer
Dr Clay Siegall studied at the University of Maryland where he got his undergraduate degree and attained his doctorate at GWU. At his age of 57 years old, he has been the CEO, chairman, president and co-founder of Seattle Genetics. Before starting his own company in 1997, Clay Siegall worked at Bristol- Myers Squibb Pharmaceutical Research Institute. Clay is the director of three other companies namely; Alder Biopharmaceuticals, Ultragenyx Pharmaceuticals and Mirna Therapeutics. He is also on the directing board of the Fred Hutchinson Cancer Research Business Alliance.
When it comes to cancer research, doctor Siegall has contributed a great deal. His company develops and commercializes therapies based on monoclonal antibodies that are used in cancer treatment. His company is one of the great in the ADC’s industry. ADCs are also known as antibody-drug conjugates are designed in such a way that their cell-killing agents target the cancer cells only and thus the healthy cells are not affected. Clay Siegall is very passionate about cancer research and has been able to develop a few drugs that could potentially change cancer treatment. He owes his success to not taking no for an answer. His determination can be seen in these four drugs that have done really well in the pharmaceutical industry.
Recently approved by the FDA, adcetris holds a lot of potentials. The drug was approved to be used on patients who do not respond to the first treatment. If the drug performs well on the research market, it could be a game changer in the oncology field. Studies on the drug are still going on, and more improvements will be made.
The drug next in line is the number 33A. The drug is used in the treatment of AML also known as acute myeloid leukemia, one of the most dreadful diagnoses. There are very few treatments for AML. This drug has had a rough patch after being halted by the FDA. This was after four patients died while receiving the treatment. Studies were however reopened after it was found out that the death of the four patients had nothing to do with the drug.
The third and fourth drug are 22E and LIV1 respectively. 22E is intended for the treatment of bladder cancer. LIV1 is used in the treatment of breast cancer. These drugs if perfected could be a better option compared to radiation and chemotherapy.